Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer

Phase 3

Recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Ascorbate
Drug: Nab paclitaxel
Drug: Gemcitabine

First Posted Date: 2023-08-31

Last Posted Date: 2023-12-06

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT06018883

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI

Phase 2

Recruiting

Conditions: Brain Metastases
Non-small Cell Lung Cancer

Interventions: Drug: EGFR-TK Inhibitor
Radiation: Stereotactic radiotherapy

First Posted Date: 2023-08-31

Last Posted Date: 2023-08-31

Lead Sponsor: Fudan University

Target Recruit Count: 202

Registration Number: NCT06020066

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer

Phase 2

Recruiting

Conditions: Terminal Cancer
Metastatic Pancreatic Cancer

Interventions: Drug: Ascorbate

First Posted Date: 2023-08-31

Last Posted Date: 2024-06-06

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT06018896

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer

Phase 3

Recruiting

Conditions: Pancreatic Cancer Stage IV
Chemotherapy-induced Nausea and Vomiting

Interventions: Drug: Thalidomide
Drug: Nab paclitaxel
Drug: Placebo
Drug: Gemcitabine

First Posted Date: 2023-08-30

Last Posted Date: 2023-11-24

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT06017284

Locations: 🇨🇳
Shanghai Cancer Center, Shanghai, Shanghai, China

Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC

Phase 2

Recruiting

Conditions: Colorectal Cancer

Interventions: Drug: Fruquintinib+mFOLFOX6/FOLFIRI

First Posted Date: 2023-08-25

Last Posted Date: 2023-08-25

Lead Sponsor: Fudan University

Target Recruit Count: 92

Registration Number: NCT06010888

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)

Phase 3

Recruiting

Conditions: TNBC - Triple-Negative Breast Cancer

Interventions: Drug: Camrelizumab Plus Chemotherapy and Famitinib
Drug: Camrelizumab Plus Chemotherapy

First Posted Date: 2023-08-21

Last Posted Date: 2024-02-21

Lead Sponsor: Fudan University

Target Recruit Count: 424

Registration Number: NCT05999149

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai, Shanghai, China

PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II

Recruiting

Conditions: Gynecologic Cancer

First Posted Date: 2023-08-21

Last Posted Date: 2023-09-29

Lead Sponsor: Fudan University

Target Recruit Count: 2935

Registration Number: NCT06001099

Locations: 🇨🇳
Fudan university shanghai cancer center, Deparment of gynecologic oncology, Shanghai, Shanghai, China

Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

Phase 2

Recruiting

Conditions: Differentiated Thyroid Cancer

Interventions: Drug: surufatinib

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-14

Lead Sponsor: Fudan University

Target Recruit Count: 32

Registration Number: NCT05989425

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Pulmonary Ventilation Function Between Patients With Primary and Recurrent Incisional Hernia: a Cross-sectional Study

Completed

Conditions: Incisional Hernia
Recurrent Hernia
COPD
Pulmonary Ventilation Function

Interventions: Behavioral: the incisional hernia recurrent

First Posted Date: 2023-08-14

Last Posted Date: 2023-08-16

Lead Sponsor: Fudan University

Target Recruit Count: 164

Registration Number: NCT05991024

Locations: 🇨🇳
Yiming Lin, Shanghai, China

Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC

Phase 1

Recruiting

Conditions: HER2-positive Gastric Cancer
Immunotherapy

Interventions: Drug: Disitamab Vedotin combined with fruquintinib and Tislelizumab

First Posted Date: 2023-08-09

Last Posted Date: 2023-08-09

Lead Sponsor: Fudan University

Target Recruit Count: 43

Registration Number: NCT05982834

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy